Figure 6. Analysis of mRNA expression of bcr-abl gene in SUP-B15 cells. The cells were treated with indicated oridonin, imatinib, or in combination for 24 h. Total RNA was isolated and RT-PCR was performed with β-actin primers as a control with the same amount of RNA. Oridonin, imatinib alone, or thier combination had no effects on the mRNA expression of bcr-abl gene in SUP-B15 cells. (A) Lane 1: control; Lane 2: oridonin 5 μM; Lane 3: oridonin 10 μM; Lane 4: oridonin 15μM; Lane 5: β-actin of conrtol; Lane 6: β-actin of oridonin 5μM; Lane 7: β-actin of oridonin 10μM. Lane 8: β-actin of oridonin 15 μM. (B) Lane 1: control; Lane 2: oridonin 3μM; Lane 3: imatinib 1μM; Lane 4: oridonin 3μM and imtinib 1μM; Lane 5: β-actin of control; Lane 6: β-actin of oridonin 3 μM; Lane 7: β-actin of imatinib 1μM; Lane 5: β-actin of oridonin 3 μM and imatinib 1 μM.